| |JULY 20249ORCHID PHARMA & CIPLA TEAM TO UNVEIL NEW DRUG IN INDIABAYER & RAD AI PARTNER TO BRING AI RADIOLOGY SOLUTIONSBayer, a leading pharmaceutical firm and Rad AI have declared a partnership to offer Rad AI's advanced AI radiology operational solutions to calantic digital solution customers. In addition to Bayer's CalanticTM Digital Solutions platform, Rad AI's radiology speech recognition reporting solution, AI-driven patient follow-up management, and automated radiology impression generation technologies make it possible for more hospitals and health systems to benefit from Rad AI's generative AI capabilities. This partnership allows Radiology suites to take advantage of operational Radiology AI applications and a scalable deployment platform integrated through one vendor.Rad AI assists radiologists with making reports quicker by utilizing generative AI to sort out radiology reports for radiologists permitting them to focus on perusing concentrates as well as coordinating stable discoveries from earlier reports. Rad AI Omni Impressions produces modified radiology report impressions from directed discoveries, customized to every radiologist's language preferences and serving to diminishing exhaustion. The follow-up process for incidental findings is automated by Rad AI Continuity, facilitating prompt patient follow-up and potentially increasing imaging revenue for health systems."Rad AI and Bayer are dedicated to pioneering innovations that serve hospitals and health systems, allowing for greater access to these advanced technologies. This relationship allows for expanded use of our cutting-edge solutions in hospitals across the country," Doktor Gurson, co-founder and CEO of Rad AI. POOrchid Pharma a Chennai-based Indian pharmaceutical firm, has declared the availability of a new drug, cefepime-enmetazobactam, which has been endorsed for the treatment of complex urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia. In a historic collaboration, Orchid Pharma has teamed with Cipla to enable the widespread and speedy distribution of this breakthrough antibiotic combination throughout India.The introduction of cefepime-enmetazobactam represents a huge step forward for India's pharmaceutical industry in the fight against AMR, a growing worldwide health concern, and reinforces India's leadership in medical innovation. Orchid Pharma and Cipla believe that this collaboration will establish a new standard for addressing key healthcare concerns through strategic collaborations and sophisticated research. The collaboration between Orchid Pharma and Cipla brings together Orchid's novel medicine development skills with Cipla's substantial distribution network and market presence. This alliance intends to get this life-saving drug to healthcare providers across India as fast and efficiently as feasible.Speaking on the launch, Manish Dhanuka, managing director Orchid Pharma said, "With increasing resistance to the current drugs most commonly used for treatment of these indications ­ e.g. piperacillin-tazobactam for cUTI ­ doctors were forced to start using carbapenems ­ a reserve drug meant to be used when most other drugs don't work. Now, Orchid's cefepime-enmetazobactam will allow doctors to spare carbapenems, prolonging their effective life by restricting their use." PO
< Page 8 | Page 10 >